ad17002
Biologicalexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Mar 26, 2019 (NCT04088721)
Timeline
Indications
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07250594 | Phase 2 | Dec 31, 2025 | Advagene |
| NCT05985694 | Phase 2 | Nov 27, 2023 | Advagene, Taipei Medical University |
| NCT05541510 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2022 | Advagene, Gadjah Mada University |
| NCT05069610 | Phase 1/Phase 2 (Phase 2) | Oct 15, 2021 | Advagene |
| NCT04088721 | Phase 1/Phase 2 (Phase 2) | Mar 26, 2019 | Advagene, Clinipace LTD, Taipei Medical University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advagene | For profit | 5 | 5 | 2 | 2019 |
| Taipei Medical University | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Clinipace LTD | For profit | 1 | 0 | 1 | 2019 |
| Gadjah Mada University | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1